Arabic Arabic English English French French German German
dark

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Cara Therapeutics (Nasdaq: CARA) and Vifor Pharma today announced that the U.S. Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Patient Interactive Systems Minimizes Nurse Burnout & Facilitates Patient Education

Next Post

Kelyniam Global Releases 2nd Quarter 2021 Financials Maintains Profitability – Covid Challenges Continue

Related Posts
Total
0
Share